{
    "clinical_study": {
        "@rank": "137868", 
        "arm_group": {
            "arm_group_label": "Vemurafenib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, multicenter study will evaluate the pharmacokinetics, safety and efficacy\n      of Zelboraf (vemurafenib) in Chinese patients with BRAFV600 mutation-positive unresectable\n      or metastatic melanoma. Patients will receive Zelboraf 960 mg orally twice daily until\n      disease progression or unacceptable toxicity occurs."
        }, 
        "brief_title": "A Study of Zelboraf (Vemurafenib) in Chinese Patients With BRAFV600 Mutation-Positive Unresectable or Metastatic Melanoma", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chinese male or female patients, >/= 18 years of age\n\n          -  Histologically confirmed metastatic melanoma (surgically unresectable Stage IIIc or\n             Stage IV, American Joint Committee on Cancer)\n\n          -  Treatment-na\u00efve or having received prior systemic treatments for metastatic melanoma\n\n          -  Positive BRAFV600 mutation result determined by a designated laboratory using the\n             Cobas 4800 BRAFV600 Mutation Test\n\n          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n\n          -  Previous allowed chemotherapy, immunotherapy, or radiation therapy must have been\n             completed at least 2 weeks prior to study drug administration, and all associated\n             toxicity must be resolved (to </= Grade 1 or baseline)\n\n          -  Recovery from effects of any major surgery (excluding tumor biopsy at baseline) or\n             significant traumatic injury at least 14 days before the first dose of study\n             treatment\n\n          -  Adequate hematologic, renal, and liver function as defined by protocol\n\n          -  Fertile men and women must use an effective method of contraception during treatment\n             and for at least 6 months after completion of treatment as directed by their\n             physician (in accordance with local requirements).\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Life expectancy > 3 months\n\n          -  Able to swallow pills\n\n        Exclusion Criteria:\n\n          -  Active CNS lesions (i.e. radiographically unstable, symptomatic lesions)\n\n          -  History of or known spinal cord compression or carcinomatous meningitis\n\n          -  Anticipated or ongoing administration of anti-cancer therapies other than those\n             administered in this study\n\n          -  Active SCC that has not been excised or has not yet adequately healed post excision\n\n          -  Pregnant or lactating women\n\n          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant\n             small bowel resection that would preclude adequate vemurafenib absorption\n\n          -  Any of the following within the 6 months prior to study drug administration:\n             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass\n             graft, symptomatic congestive heart failure, serious cardiac arrhythmia requiring\n             medication, uncontrolled hypertension, cerebrovascular accident or transient ischemic\n             attack, or symptomatic pulmonary embolism\n\n          -  Known clinically significant active infection\n\n          -  History of allogeneic bone marrow transplantation or organ transplantation\n\n          -  Previous malignancy within the past 5 years other than adequately treated basal cell\n             carcinoma or SCC of the skin, melanoma in-situ, and carcinoma in-situ of the cervix\n             and/or curatively treated cancer, from which the patient is currently disease-free,\n             or any malignancy from which the patient has been continuously disease-free for at\n             least 5 years\n\n          -  Previous treatment with a BRAF inhibitor (sorafenib allowed) or MEK inhibitor\n\n          -  Patients who have had at least one dose of study drug (vemurafenib) in a previous\n             clinical trial that includes vemurafenib\n\n          -  Known HIV positivity or AIDS-related illness, or known hepatitis B virus or hepatitis\n             C virus infection\n\n          -  Received any investigational treatment within 4 weeks of study drug start"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910181", 
            "org_study_id": "YO28390"
        }, 
        "intervention": {
            "arm_group_label": "Vemurafenib", 
            "description": "960 mg orally BID", 
            "intervention_name": "vemurafenib [Zelboraf]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100142"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "zip": "510060"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Open Label, Multicenter, Multiple-dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAFV600 Mutation-positive Unresectable or Metastatic Melanoma", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 21"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 21"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910181"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Best overall response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}